美国食品和药物管理局(FDA)周三表示，已批准更改礼来公司阿尔茨海默氏症药物Kisunla的处方信息，允许更渐进地给药，以降低潜在的脑肿胀风险。一年多前的一项研究显示，与安慰剂相比，Kisunla能将记忆和思维问题的恶化速度减缓29%，因此FDA批准将其用于早期阿尔茨海默氏症成人患者。
美国食品和药物管理局(FDA)周三表示，已批准更改礼来公司阿尔茨海默氏症药物Kisunla的处方信息，允许更渐进地给药，以降低潜在的脑肿胀风险。一年多前的一项研究显示，与安慰剂相比，Kisunla能将记忆和思维问题的恶化速度减缓29%，因此FDA批准将其用于早期阿尔茨海默氏症成人患者。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.